Display options
Cite
Araújo TM, Seabra AD, Lima EM, et al. Recurrent amplification of RTEL1 and ABCA13 and its synergistic effect associated with clinicopathological data of gastric adenocarcinoma. Mol Cytogenet. 2016;9:52doi: 10.1186/s13039-016-0260-x.
Araújo, T. M., Seabra, A. D., Lima, E. M., Assumpção, P. P., Montenegro, R. C., Demachki, S., Burbano, R. M., & Khayat, A. S. (2016). Recurrent amplification of RTEL1 and ABCA13 and its synergistic effect associated with clinicopathological data of gastric adenocarcinoma. Molecular cytogenetics, 952. https://doi.org/10.1186/s13039-016-0260-x
Araújo, T M, et al. "Recurrent amplification of RTEL1 and ABCA13 and its synergistic effect associated with clinicopathological data of gastric adenocarcinoma." Molecular cytogenetics vol. 9 (2016): 52. doi: https://doi.org/10.1186/s13039-016-0260-x
Araújo TM, Seabra AD, Lima EM, Assumpção PP, Montenegro RC, Demachki S, Burbano RM, Khayat AS. Recurrent amplification of RTEL1 and ABCA13 and its synergistic effect associated with clinicopathological data of gastric adenocarcinoma. Mol Cytogenet. 2016 Jun 29;9:52. doi: 10.1186/s13039-016-0260-x. eCollection 2016. PMID: 27366209; PMCID: PMC4928298.
Copy Download .nbib Format: NLM
Share it on

Mol Cytogenet. 2016 Jun 29;9:52. doi: 10.1186/s13039-016-0260-x. eCollection 2016.

Recurrent amplification of RTEL1 and ABCA13 and its synergistic effect associated with clinicopathological data of gastric adenocarcinoma.

Molecular cytogenetics

T M Araújo, A D Seabra, E M Lima, P P Assumpção, R C Montenegro, S Demachki, R M Burbano, A S Khayat

Affiliations

  1. Human Cytogenetics Laboratory, Federal University of Pará, Belém, 66075-110 Pará Brazil.
  2. Oncology Research Center, Federal University of Pará, Belém, 66073-000 Pará Brazil.
  3. Molecular Biology Department, Federal University of Paraíba, João Pessoa, 58051-900 Paraíba Brazil.

PMID: 27366209 PMCID: PMC4928298 DOI: 10.1186/s13039-016-0260-x

Abstract

BACKGROUND: Despite progression in treatment of gastric cancer, prognosis of patients remains poor, in part due to the low rate of diagnosis during its early stages. This paradigm implies the necessity to identify molecular biomarkers for early gastric cancer diagnosis, as well as for disease monitoring, thus contributing to the development of new therapeutic approaches. In a previous study, performed by array-Comparative Genomic Hybridization, we described for the first time in literature recurrent amplification of RTEL1 and ABCA13 genes in gastric cancer. Thus, the aim of the present study was to validate recurrent amplification of RTEL1 and ABCA13 genes and associate CNV status with clinicopathological data.

FINDINGS: Results showed RTEL1 and ABCA13 amplification in 38 % of samples. Statistical analysis demonstrated that RTEL amplification is more common in older patients and more associated with intestinal type and ABCA13 amplification increases the risk of lymph node metastasis and is more common in men. Co-amplification of these genes showed a significant association with advanced staging.

CONCLUSIONS: aCGH is a very useful tool for investigating novel genes associated with carcinogenesis and RTEL1 amplification may be important for the development of gastric cancer in older patients, besides being a probable event contributing for chromosomal instability in intestinal gastric carcinogenesis. ABCA13 amplification may have age-specific function and could be considered a useful marker for predicting lymph node metastasis in resected gastric cancer patients in early stage. Lastly, RTEL1 and ABCA13 synergistic effect may be considered as a putative marker for advanced staging in gastric cancer patients.

Keywords: ABCA13; Biomarkers; Gastric cancer; RTEL1; aCGH

References

  1. Nat Rev Drug Discov. 2006 Mar;5(3):219-34 - PubMed
  2. Cell. 2008 Oct 17;135(2):261-71 - PubMed
  3. Diagn Mol Pathol. 2013 Sep;22(3):127-37 - PubMed
  4. Cell Oncol. 2004;26(5-6):307-17 - PubMed
  5. Mod Pathol. 2015 Sep;28(9):1174-84 - PubMed
  6. Mol Cancer. 2015 Feb 18;14:44 - PubMed
  7. IARC Sci Publ. 2004;(157):327-49 - PubMed
  8. Cancer Res. 1998 Jan 1;58(1):34-7 - PubMed
  9. Nucleic Acids Res. 2011 Mar;39(5):1647-55 - PubMed
  10. J Gastroenterol. 2000;35 Suppl 12:111-5 - PubMed
  11. PLoS One. 2011 Jan 31;6(1):e14632 - PubMed
  12. Transgenic Res. 2012 Oct;21(5):1109-15 - PubMed
  13. Hum Genomics. 2009 Apr;3(3):281-90 - PubMed
  14. Acta Pathol Microbiol Scand. 1965;64:31-49 - PubMed
  15. Br J Cancer. 2001 Sep 1;85(5):697-704 - PubMed
  16. Epidemiol Rev. 1996;18(2):218-34 - PubMed
  17. Am J Pathol. 2006 Apr;168(4):1375-84 - PubMed
  18. Toxicol Pathol. 2012 Dec;40(8):1160-8 - PubMed
  19. Oncol Lett. 2015 Apr;9(4):1502-1508 - PubMed
  20. Am J Epidemiol. 2007 Jun 15;165(12):1424-33 - PubMed
  21. BMC Genomics. 2007 Oct 01;8:345 - PubMed
  22. Cell. 2004 Jun 25;117(7):873-86 - PubMed
  23. J Korean Med Sci. 2006 Aug;21(4):656-65 - PubMed
  24. Mutagenesis. 2012 Mar;27(2):187-96 - PubMed
  25. Anticancer Res. 2006 Jul-Aug;26(4B):2909-14 - PubMed
  26. Am J Pathol. 1999 Jan;154(1):37-43 - PubMed
  27. Genes Chromosomes Cancer. 2000 Oct;29(2):110-6 - PubMed
  28. Mutagenesis. 2010 May;25(3):213-21 - PubMed
  29. Annu Rev Cell Biol. 1992;8:67-113 - PubMed
  30. World J Gastroenterol. 2014 Apr 14;20(14):3967-75 - PubMed
  31. J Clin Oncol. 2011 Dec 20;29(36):4789-95 - PubMed
  32. Genes Chromosomes Cancer. 1997 Sep;20(1):38-43 - PubMed
  33. BMC Cancer. 2010 Oct 06;10:530 - PubMed
  34. Genes Chromosomes Cancer. 2008 Sep;47(9):755-65 - PubMed
  35. Nucleic Acids Res. 2006 May 08;34(8):2408-17 - PubMed
  36. Anticancer Res. 2014 Nov;34(11):6405-15 - PubMed
  37. Lancet. 2010 Aug 28;376(9742):687-97 - PubMed
  38. Pharmacogenomics. 2013 Apr;14(5):515-29 - PubMed
  39. Expert Rev Mol Med. 2014 Jan 23;16:e1 - PubMed

Publication Types